文献速递肾移植

ABO血型不相容肾移植中抗体介导排斥反应:Banff 2022可能过度诊断

Antibody-mediated rejection in ABO-incompatible kidney transplantation.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

ABOi组新发抗HLA DSA和临床AMR率更低;Banff 2022使56%的ABOi活检符合AMR标准,但MMDx仅确认14%为分子AMR。C4d在ABOc活检中驱动分子AMR活性。

要点

  • ABOi肾移植新发抗HLA DSA和临床AMR风险低于ABOc。
  • Banff 2022在ABOi中可能过度诊断AMR,MMDx可鉴别适应与排斥。
  • ABOc活检中C4d沉积本身驱动分子AMR活性,即使未达组织学AMR诊断。

核心结论

  • ABOi移植降低新发抗HLA DSA风险。
  • Banff 2022标准可能过度诊断ABOi肾移植中的AMR。
  • 基于活检的转录诊断可区分抗HLA/抗A/B介导的免疫损伤与适应导致的C4d沉积。
  • 在ABOc活检中,C4d沉积驱动分子AMR活性。

研究设计与样本

  • 分析66例ABOi和251例ABOc肾移植受者的抗HLA DSA。
  • 25例ABOi方案活检行MMDx,并与ABOc活检比较:35例DSA阴性/C4d阴性/MVI<2、16例C4d阳性/MVI<2、35例DSA阳性/C4d阴性/MVI=1(可能AMR)、87例C4d阴性或阳性/MVI≥2。

主要发现

  • ABOi组新发抗HLA DSA率低于ABOc组(P = .001)。
  • ABOi组临床AMR率低于ABOc组(P = .018)。
  • 25例ABOi活检中56%因抗A/B DSA符合AMR标准:20%活动性AMR、20%可能AMR、16%慢性AMR。
  • MMDx仅确认14%为分子AMR(P < .001)。
  • ABOi与DSA阴性/C4d阴性ABOc且MVI低于阈值的活检在分子排斥、原型和病变评分上无差异(P > .05),移植功能稳定。

关键数值与推荐

  • ABOi中C4d沉积与适应相关而非排斥,抗A/B同种凝集素也归类为DSA,因此AMR诊断主要依赖微血管炎症(MVI)。
  • MMDx用于25例ABOi方案活检的分子AMR确认。

临床怎么用

  • ABOi肾移植受者应关注新发抗HLA DSA风险较低的特点。
  • 依据Banff 2022诊断ABOi的AMR时需谨慎,避免过度诊断。
  • 活检转录诊断有助于鉴别抗HLA/抗A/B介导损伤与适应所致C4d沉积。
  • ABOc活检中C4d沉积即使未达组织学AMR诊断也应关注分子AMR活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: In ABO-incompatible (ABOi) kidney transplantation, C4d deposition is associated with accommodation rather than rejection. Isoagglutinins targeting blood group antigens A/B are also classified as donor-specific antibodies (DSA). Therefore, the diagnosis of antibody-mediated rejection (AMR) relies primarily on microvascular inflammation (MVI). METHODS: We analyzed 66 ABOi and 251 ABO-compatible (ABOc) kidney transplant recipients (KTRs) concerning anti-human leukocyte antigen (HLA) DSA development. Forty-six protocol biopsies from ABOi KTRs were classified according to Banff 2022. In addition, 25 ABOi protocol biopsies were assessed by the Molecular Microscope Diagnostics System (MMDx) and compared with ABOc biopsies: (i) 35 DSA-negative, C4d-negative cases with MVI <2, (ii) 16 C4d-positive cases with MVI <2, (iii) 35 DSA-positive, C4d-negative cases with MVI = 1 (probable AMR) and (iv) 87 C4d-negative/positive cases with MVI ≥2. RESULTS: ABOi KTRs showed lower rates of de novo anti-HLA DSA (P = .001) and clinical AMR (P = .018) than ABOc KTRs. Among 25 ABOi protocol biopsies analyzed with MMDx, 56% met AMR criteria due to anti-A/B DSA: 20% active AMR, 20% probable AMR and 16% chronic AMR. However, molecular AMR was confirmed in only 14% by MMDx (P < .001). ABOi and DSA-negative, C4d-negative ABOc biopsies with an MVI below threshold did not differ in molecular rejection, archetype and lesion scores (P > .05) and showed stable graft function. Molecular AMR classifier scores were significantly lower in ABOi and DSA-negative, C4d-negative ABOc cases with MVI below threshold compared with C4d-positive ABOc and ABOc cases with probable AMR (P = .007). Notably, C4d drives molecular AMR activity in ABOc biopsies already at C4d1 levels by immunofluorescence (P = .011) and even in the absence of a histological Banff AMR diagnosis (P = .003). CONCLUSION: ABOi transplantation reduces the risk of developing de novo anti-HLA DSA. Banff 2022 criteria may over-diagnose AMR. Biopsy-based transcript diagnostics differentiate anti-HLA- and anti-A/B-mediated alloimmune injury from C4d deposition due to accommodation. Interestingly, C4d deposition drives molecular AMR activity in ABOc biopsies.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Castrezana Lopez K, Weidmann L, Harmacek D, et al. Antibody-mediated rejection in ABO-incompatible kidney transplantation. Nephrol Dial Transplant. 2026. PMID: 41124036. doi:10.1093/ndt/gfaf224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。